HomeToday’s HighlightsThe Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals. The Amgen/Novartis story. A Little Curiosity About Alder Biopharmaceuticals. Today’s Highlights April 8, 2019 The Amgen/Novartis Story In May 2018 Amgen (AMGN) & Novartis (This content is for paid subscribers. Please click here to subscribe or here to log in. Today’s Highlights Alder BioPharmaceuticals (ALDR), Amgen (AMGN), Novartis (NVS) April 8, 2019 Tweet Pin It Other Articles Alnylam Pharmaceuticals Receives EC Approval for AMVUTTRA® for the Treatment of ATTR Amyloidosis with Cardiomyopathy June 9, 2025 0 Important News For Vera Therapeutics June 2, 2025 0 Alnylam Pharmaceuticals Reported Its Q1 2025 Financial Results and Highlights Recent Period Progress May 1, 2025 0 BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions March 24, 2025 0